Latest Biogen News & Updates
See the latest news and media coverage for Biogen. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company for neurological, immune, and rare diseases
biogen.com- Headquarters
- Cambridge, United States
- Company type
- Public company
- Number of employees
- 7,500–10,000
Last updated
Latest news about Biogen
In short: Biogen outperformed first-quarter profit expectations, expanded its immunology pipeline via acquisitions, and received FDA approval for Spinraza.
Company announcements
-
Biogen announces FDA extends LEQEMBI IQLIK review
FDA extends sBLA review by three months to August 24, 2026, for subcutaneous starting dose in early Alzheimer’s. No approvability concerns raised.
-
Biogen doses first patient in Phase 3 SMA study
This milestone advances potential new treatments for SMA patients and families. Ongoing research targets unmet needs.
-
Biogen hosts Q1 2026 financial results webcast
It starts soon at 8AM ET. Interested parties can join live.
-
Biogen reports first quarter 2026 results
The announcement was made on April 29, 2026. A detailed document is available for download.
Media coverage
-
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous I...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three...
-
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate
The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer's disease.
-
Biogen Inc. (BIIB) - Q1 2026 Earnings Beat Drives 6% Single-Day Gain Despite...
Our platform offers futures positioning, options market sentiment, and volatility analysis for comprehensive derivatives coverage. Understand market bias with our comprehensive derivatives analysis ...
-
Biogen beats profit expectations as demand for newer rare-disease drugs fuel growth
Biogen reports strong first-quarter earnings with rising sales from new Alzheimer's and rare-disease treatments, despite declining demand for older multiple sclerosis drugs. The drugmaker's strategy...
Track Biogen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Biogen competitors & trending companies
Browse news for competitors to Biogen and other trending companies.
Ipsen
Sobi
Mirum Pharmaceuticals
UCB
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable